We collected data from patients with confirmed COVID-19 hospitalized in our unit from March 2020 through November 2020. We included patients aged >18 years, with a positive RT-PCR for SARS-CoV-2, supplemental oxygen requirement, and abnormal chest imaging that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Severe COVID-19 pneumonia was defined as dyspnea, with at least one of the following: a respiratory rate of 30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2) of less than 300 mm Hg, or pulmonary infiltrates in more than 50% of the lung fields.14

We excluded patients with a hospital stay less than 24 h, patients without oxygen requirement or patients that received any other therapies such as convalescent plasma, tocilizumab, remdesivir or methylprednisolone.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.